Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules

By Burstein Harold   Overmoyer Beth   Gelman Rebecca   Silverman Paula   Savoie Jennifer   Clarke Kathryn   Dumadag Leda   Younger Jerry   Ivy Percy   Winer Eric  

Investigational New Drugs, Vol. 25, Iss. 2, 2007-04 ,pp. : 161-164

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

By Goldstein D.   Ackland S.   Bell D.   Olver I.   Davis I.   Rosenthal M.   Toner G.   Pinel M.   Byrne M.  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 429-434

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

By Alva Ajjai  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 749-757

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma

By Shaheen Philip   Stadler Walter   Elson Paul   Knox Jennifer   Winquist Eric   Bukowski Ronald  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 577-581

Springer Publishing Company

Access to resources Recommend Favorite

Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer

By Dowlati Afshin   Chapman Robert   Subbiah Shanmuga   Fu Pingfu   Ness Anne   Cortas Tania   Patrick Lauren   Reynolds Sherrie   Xu Natalie   Levitan Nathan   Ivy Percy   Remick Scot  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 563-567

Springer Publishing Company

Access to resources Recommend Favorite